ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2227 • ACR Convergence 2024

    Worrisome Mortality Trends over 20 Years Among Patients with Underlying Ischemic Heart Disease and Rheumatoid Arthritis

    Yukthi Mudiam1 and Shreyas Singireddy2, 1Apollo Institute of Medical Sciences and Research, Richmond, TX, 2Department of Cardiology, University of Illinois College of Medicine, Peoria, IL

    Background/Purpose: Ischemic heart disease (IHD) is one of the leading causes of death in the United States. Rheumatoid arthritis (RA), a chronic inflammatory condition affecting…
  • Abstract Number: 2243 • ACR Convergence 2024

    A Cross-sectional Study of the Association Between Anxiety State and Various Factors in Patients with Rheumatoid Arthritis

    Yusuke Miwa1, Yuko Miwa2 and Michio Hosaka3, 1Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Tokyo, Japan, 2Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Setagaya-ku, Tokyo, Japan, 3Department of psychosomatic medicine, Katsuyama Clinic, Kawaguchiko, Yamanashi, Japan

    Background/Purpose: Although the complication of anxiety in rheumatoid arthritis (RA) patients is reported to be 1.2 times higher than in healthy controls and weakly correlated…
  • Abstract Number: 2263 • ACR Convergence 2024

    The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies

    Gilad Halpert1, Ori Moskovitch2, Linoy Israel2, Eri Govrin2, Boris Gilburd2, Ori Segal2, Adi Anaki3, Tal Caller2, Daniel Yechiali2, Shlomo Segev2, Omer Gendelman4, Abdulla Watad5, Ruty Mehrian-Shai2, Rachella Popovtzer3 and Howard Amital6, 1CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, 2Sheba Medical Center, Ramat-Gan, Israel, 3Bar Ilan University, Ramat-Gan, Israel, 4Sheba Medical Center, Ramat Gan, Israel, 5Tel Hashomer Medical Center, Ramat Gan, Israel, 6Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel

    Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
  • Abstract Number: 2281 • ACR Convergence 2024

    Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab

    Monica Luque1, Kristina Zhelyazkova1, Laxmikant Vashishta2, Masna Rai3, Abid Sattar4, Richard Bucknall4, Steffen Leutz3 and FAUSTO BERTI1, 1Alvotech, Zürich, Switzerland, 2Alvotech, Bangalore, India, 3Alvotech, Jülich, Germany, 4Alvotech, London, United Kingdom

    Background/Purpose: Golimumab is a safe and effective treatment for RA. Biosimilars to the reference product (RP) may make treatment more accessible. We assessed comparable efficacy…
  • Abstract Number: 2553 • ACR Convergence 2024

    Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study

    Mark Russell1, Mark Gibson2, Benjamin Zuckerman1, Kanta Kumar3, Shirish Dubey4, Maryam Adas2, Edward Alveyn2, Samir Patel1, Zijing Yang1, Katie Bechman2, Elizabeth Price5, Sarah Gallagher6, Andrew Cope2, Sam Norton1 and James Galloway7, 1King's College London, London, England, United Kingdom, 2King's College London, London, United Kingdom, 3University of Birmingham, Birmingham, United Kingdom, 4Oxford University Hospitals NHS FT, Oxford, United Kingdom, 5Great Western Hospital NHS Foundation Trust, Swindon, England, United Kingdom, 6British Society for Rheumatology, London, United Kingdom, 7Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose: Quantifying healthcare inequality is essential to addressing the imbalance in outcomes attributable to age, gender, ethnicity and multimorbidity. In this study, we analysed differences…
  • Abstract Number: 2673 • ACR Convergence 2024

    Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis

    Diane Lacaille1, Coraline Danieli2, Kasra Moolooghy1 and Michal Abrahamowicz3, 1Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 2Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, 3McGill University, Verdun, Canada

    Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
  • Abstract Number: 0045 • ACR Convergence 2024

    Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins

    Khushali Trivedi1, Clarissa Klenke2, Jun Kim1, Jeba Atkia Maisha2, Alina Sememenko1, XIAOBO MENG2, Mario Navarrete1, Hani El-Gabalawy2 and Liam O'Neil2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
  • Abstract Number: 0063 • ACR Convergence 2024

    Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils

    Rayan Najjar1, Noga Rogel2 and Tomas Mustelin3, 1University of Washington, Seattle, 2University of Washinton, Seattle, 3University of Washington, Seattle, WA

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…
  • Abstract Number: 0152 • ACR Convergence 2024

    Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases

    Janett Riega Torres1, Karina Palomo-Arnaud2, Gabriel Figueroa-Parra1, Fernando Morales Wong1, Jesús Hernán González Cortés1, Jesus Mohamed Hamsho1, Jorge Esquivel-Valerio1, Dionicio Galarza-Delgado3 and Karim Mohamed Noriega1, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 3UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology.  Retinal toxicity is an unwanted side effect…
  • Abstract Number: 0232 • ACR Convergence 2024

    Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study

    Seyyid Bilal Acikgoz1, Ricardo Sabido-Sauri2, Ozun Bayindir Tsechelidis3, Ummugulsum Gazel2, Sylvia Sangwa4, Elliot Hepworth2 and Sibel Aydin5, 1University of Ottawa, Rheumatology, Ottawa, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3Ottawa University, Ottawa, ON, Canada, 4The Ottawa Hospital Research Institute, Ottawa, Canada, 5University of Ottawa - Ottawa, Ottawa, ON, Canada

    Background/Purpose: In the era of several advanced therapies and an increasing number of patients with rheumatoid arthritis (RA) who have been failed by multiple therapies,…
  • Abstract Number: 0427 • ACR Convergence 2024

    Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease

    Lucy Masto1, Amaya Smole2, Ranqing Lan1, Michael Parides1, Caroline Siegel1, Sarah Lieber1, Jonah Levine1, Bessie Stamm1, Lisa Mandl1, Michael Lockshin3, Lisa Sammaritano4 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Amherst, MA, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, Scarsdale, NY

    Background/Purpose: The relationship between menopause and systemic rheumatic disease (SRD) severity in women with SRDs is poorly understood. Few studies evaluating this association suggest worsening…
  • Abstract Number: 0466 • ACR Convergence 2024

    Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample

    Karun Shrestha1, Prakriti Subedi2, Manoj Ghimire3, Sajana Poudel4, Keerthi Parvathaneni5, Mahmoud Hashim6, Kalpana Ghimire5, Oshna Pandey5, Mohammed Hasan7, Clement Tagoe8 and Liliya Gandrabur9, 1St. Barnabas Hospital Internal Medicine Residency, Bronx, NY, 2St. Barnabas Hospital, Bronx, NY, 3St Barnabas Hospital, BRONX, NY, 4Cook County Health, CHICAGO, NY, 5Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY 10457, USA, Bronx, NY, 6SBH Health System, New Rochelle, NY, 7Parkview Medical Center, Pueblo, CO, 8Albert Einstein College of Medicine, FRESH MEADOWS, NY, 9SBH Health System, Forest Hills, NY

    Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, effective pain management remains challenging, with many patients also experiencing insomnia, anxiety, and depression. As cannabis legalization…
  • Abstract Number: 0483 • ACR Convergence 2024

    Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD

    Misti Paudel1, Shravani Chitineni1, Ruogu Li2, Chinmayi Naik3, Nancy Shadick3, Michael Weinblatt4 and Daniel Solomon5, 1Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Prior studies have evaluated the risk factors for difficult-to-treat RA (D2T-RA) but have not applied EULAR’s full criteria for D2T-RA in a longitudinal data…
  • Abstract Number: 0500 • ACR Convergence 2024

    An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years

    Kevin Winthrop1, Daniel Aletaha2, Roberto Caporali3, Yoshiya Tanaka4, Tsutomu Takeuchi5, Vikas Modgill6, Edmund V. Ekoka Omoruyi7, Dick de Vries8, Katrien Van Beneden9, Jacques-Eric Gottenberg10 and Gerd Burmester11, 1School of Medicine, Oregon Health and Science University, Portland, OR, 2Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 4Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 5Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 6Medical Safety, Galapagos NV, Mechelen, Belgium, 7Biostatistics, Galapagos NV, Mechelen, Belgium, 8Clinical Development, Galapagos BV, Leiden, Netherlands, 9Medical Affairs, Galapagos NV, Mechelen, Belgium, 10Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 11Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
  • Abstract Number: 0516 • ACR Convergence 2024

    Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old

    Bruno Fautrel1, Alain SARAUX2, Isabelle Idier3, Henri Bonnabau4, Geoffray Bizouard5 and BERNARD COMBE6, 1INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 2CHU Brest, Brest, France, 3Chugai Pharma france, Puteaux, Ile-de-France, France, 4IQVIA France, Bordeaux, France, 5IQVIA France, La Defense, Ile-de-France, France, 6Montpellier University, LA GRANDE MOTTE, Languedoc-Roussillon, France

    Background/Purpose: Few real-life long-term data are available in RA patients initiating tocilizumab (TCZ) depending on age. The objective of this study was to compare the…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology